Market Overview

UPDATE: Jefferies Upgrades Vanda Pharmaceuticals to Buy on Tasimelteon Catalyst

Share:
Related VNDA
Vanda Pharma Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatits
JMP Feeling Mostly Good On 4 Drug, Healthcare Stocks
Horizon Pharma Up On Bullish Leerink Initiation (Investor's Business Daily)

Jefferies upgraded Vanda Pharmaceuticals (NASDAQ: VNDA) from Hold to Buy and raised the price target from $3.50 to $6.00.

Jefferies commented, "We're finally giving credit for tasimelteon given 1) surprisingly good recent Non24 Ph.3 data w/clinical sleep efficacy which likely improves FDA receptivity, 2) orphan pricing not confounded by ‘depression' efforts, and 3) approaching regulatory catalysts. We still think it's far from a slam dunk, but even conservatively discounted Tasi contribution is likely big upside from current negative EV level."

Vanda Pharmaceuticals closed at $3.95 on Wednesday.

Latest Ratings for VNDA

DateFirmActionFromTo
Mar 2015JefferiesInitiates Coverage onBuy
Feb 2015JefferiesMaintainsMarket Outperform
Jun 2014Empire Asset ManagementInitiates Coverage onSell

View More Analyst Ratings for VNDA
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Upgrades Analyst Ratings

 

Related Articles (VNDA)

Around the Web, We're Loving...